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ABSTRACT 
Immunoglobulin (IG) gene repertoire restrictions strongly support antigen selection in the 
pathogenesis of chronic lymphocytic leukemia (CLL). Given the emerging multifarious 
interactions between CLL and bystander T cells, we sought to determine whether antigen(s) 
are also selecting T cells in CLL. We performed a large-scale, next-generation sequencing 
(NGS) study of the T-cell repertoire, focusing on major stereotyped subsets representing CLL 
subgroups with undisputed antigenic drive, but also included patients carrying non-subset IG 
rearrangements to seek for T-cell immunogenetic signatures ubiquitous in CLL. Considering 
the inherent limitations of NGS, we deployed bioinformatics algorithms for qualitative 
curation of T-cell receptor rearrangements, and included multiple types of controls. Overall, 
we document the clonal architecture of the T-cell repertoire in CLL. These T-cell clones 
persist and further expand overtime, and can be shared by different patients, most 
especially patients belonging to the same stereotyped subset. Notably, these shared 
clonotypes appear to be disease-specific, as they are found in neither public databases nor 
healthy controls. Altogether, these findings indicate that antigen drive likely underlies T-cell 
expansions in CLL and may be acting in a CLL subset-specific context. Whether these are the 
same antigens interacting with the malignant clone or tumor-derived antigens remains to be 
elucidated.  
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INTRODUCTION 
Chronic lymphocytic leukemia (CLL) is characterized by remarkable skewing of the B-cell 
receptor immunoglobulin (BcR IG) repertoire, culminating in the existence of subsets of 
patients with quasi-identical, stereotyped BcR IGs. This implies antigen selection in the 
natural history of CLL, ultimately affecting clonal behavior and clinical outcome. Indeed, 
immunogenetic characteristics of the clonal BcR IGs serve as established disease prognostic 
markers, typically exemplified by the subdivision of CLL cases into those with no or limited 
somatic hypermutation (SHM) within the clonotypic IGs (“unmutated” U-CLL) who generally 
experience an aggressive disease course versus those with a significant SHM load within 
their IG genes (“mutated", M-CLL) who display a considerably more indolent disease (1-3). 
Furthermore, certain stereotyped CLL subsets are associated with either aggressive (i.e. 
subset #1 and subset #2) or indolent clinical course (i.e. subset #4) (2, 4-6). This 
immunogenetic evidence for antigen involvement in CLL pathogenesis has been recently 
complemented by clinical evidence where drugs inhibiting key elements of BcR signaling 
have proven highly efficacious, leading to their accelerated approval for the treatment of 
patients with CLL (7-10). 
Extracellular cues that are vital for CLL cell survival and proliferation are also provided by 
accessory cells, which, together with cytokines and chemokines, form the tumor 
microenvironment (11). T cells appear to be a critical component of this microenvironment, 
as evidenced by animal model experiments demonstrating that CLL cell engraftment and 
clonal expansion depend on trophic signals provided by autologous T cells (12).  However, 
despite accumulating evidence of an intricate crosstalk between T cells and CLL B cells (13-
15), little is known regarding the role of antigen(s) in the selection and activation of cognate 
T cells. This is highly relevant in light of CLL and T cell interactions inducing T-cell tolerance, 
especially since reversal of this tolerance by immunomodulating drugs acting at the level of 
the immune synapse between clonal B and T cells shows promising results in clinical trials 
(16-18).  
Using low-throughput subcloning techniques followed by Sanger sequencing in 58 CLL 
patients, we recently reported T-cell receptor beta chain (TRB) gene repertoire restriction, 
pointing to antigenic selection (19). However, due to the inherent limitations of low-
throughput analysis, definitive conclusions were not possible. Here, we sought to advance 
the analytical depth of our approach by employing high-throughput, next generation 
sequencing (NGS). Our analysis was intentionally biased towards patients expressing 
stereotyped BcR IGs, therefore cases most evidently selected by antigen. Additionally, we 
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included M-CLL and U-CLL cases not assigned to stereotyped subsets in order to obtain a 
comprehensive view of the T-cell repertoire in CLL.  
We report pronounced T-cell oligoclonality, with clonotypes that persist and expand over 
time and shared clonotypes between different patients, especially those belonging to 
stereotyped subsets, which appear to be disease-specific. These findings implicate selection 
by antigenic elements that may be acting in a CLL subset-specific context. Whether these are 
the same antigens interacting with the malignant clone or tumor-derived antigens remains 
to be elucidated.  
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METHODS 
Patient group 
We analyzed 57 samples from 32 untreated CLL patients (Supplemental Table 1), and 2 
control samples from 2 healthy individuals (ages 70 and 80 year-old). Twenty-four of the 32 
CLL cases were selected based on their expression of stereotyped BcR IGs which assigned 
them to well-annotated CLL subsets. More specifically, these cases belonged to subset #4 
(n=12), subset #1 (n=8), and subset #2 (n=4) (Supplemental Table 2). The remaining 8 CLL 
cases were not assigned to stereotyped subsets, carrying either mutated (<98% IGHV 
identity to germline, n=5) or truly unmutated (100% IGHV identity to germline, n=3) BcR IGs. 
Two subset #4 and one subset #2 case were analyzed over time (two timepoints, median 
sampling interval 23 months - all patients remained untreated throughout the sampling 
period). No case had evidence of infection (neither signs nor symptoms) at sampling. The 
great majority of CLL patients were CMV and EBV seropositive, and so were both healthy 
individuals (Supplemental Table 3). The local Ethics Review Committee approved the study 
and written informed consent form was obtained from all individuals. 
 
PCR amplification of TRBV-TRBD-TRBJ gene rearrangements and library preparation 
Total cellular RNA was primarily isolated from peripheral blood mononuclear cells (n=40), 
but also purified CD4+ and CD8+ T-cell subpopulations (n=9 and n=7, respectively), bone 
marrow (n=2) or fresh lymph node (LN) tissue (n=1). Isolation of CD4+ and CD8+ T-cell 
subpopulations was performed by negative selection (RosetteSep™ Human CD4+/CD8+ T-Cell 
Enrichment Cocktail, Stemcell Technologies), resulting in >95% purity by flow cytometry. In 
all samples, starting absolute T-cell count exceeded 0.5x106 cells, in order to determine 
actual repertoire diversity instead of over-amplifying the same TRBV-TRBD-TRBJ 
rearrangements. For repertoire analyses, each category of samples was studied separately 
(PBMCs, BM, LN, CD4+ and CD8+ T cells). 
Except for two samples for which gradient RNA quantities were tested, in all other samples 1 
μg of RNA was reverse transcribed to complementary DNA (cDNA) using the SuperScript II RT 
kit (Invitrogen Life technologies, USA). TRBV-TRBD-TRBJ gene rearrangements were RT-PCR 
amplified according to the BIOMED-2 collaborative protocol (20). Amplicons were gel-
purified with the QIAGEN DNA purification columns (QIAGEN, Hilden, Germany) and used for 
library preparation (TruSeq LT, Illumina) according to the manufacturer’s instructions. PhiX 
was used at a 20% concentration to optimize library diversity.  Four runs were performed on 
the Illumina platform using the MiSeq Reagent Kit v2 (2x250bp).  
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Paired-end protocol allowed sequencing of the TRB complementarity-determining region 3 
(CDR3) twice/read, thus increasing the accuracy of results. Still, considering the inherent 
limitations of PCR-based NGS, the experimental setup included multiple internal controls: (i) 
"sample replicates", i.e. starting from aliquots of a single peripheral blood sample containing 
the same as well as varying T-cell counts (2 duplicates and 1 quadruplicate, range 0.5-18x106 
T cells),  (ii) "PCR replicates", i.e. starting from the same RNA sample [2 duplicates and 1 
quadruplicate, containing the same as well as varying RNA quantity (range 1.0-5.8 μg)], and, 
(iii) "sequencing replicates", i.e. starting from the same PCR product but sequenced in 
separate MiSeq runs (5 duplicates).  
 
Bioinformatics processing of raw data, definitions and interpretation 
Initial data filtering was performed by the Illumina signal-processing software, leading to the 
rejection of low quality and erroneous sequences. Sequences were assigned to samples 
based on incorporated indexes, and sequence segments corresponding to the adapters were 
trimmed.  In order to further increase the accuracy of results, raw NGS reads were subjected 
to a purpose-built, bioinformatics algorithm performing: (i) length and quality filtering of raw 
reads; (ii) merging of filtered-in paired reads via local alignment; (iii) length and quality 
filtering of stitched sequences. Detailed length, quality and overlap rules that were applied 
for the analysis are provided in Supplemental Table 4.  
Filtered-in sequences were submitted to IMGT/HighV-QUEST tool (http://www.imgt.org), 
and metadata was processed by an in-house bioinformatics pipeline designed for clonotype 
computation and repertoire analysis. Only productive TRBV-TRBD-TRBJ gene 
rearrangements were included in the analysis. TRBV-TRBD-TRBJ gene rearrangements 
carrying TRBV genes with <95% germline identity were also discarded as sequences with 
unacceptable error rate, given the lack of somatic hypermutation in T cells.  
Clonotypes were computed as unique pairs of TRBV genes and CDR3 amino acid sequences 
within a sample. Clonotypes were considered expanded (forming clusters) when they 
contained ≥2 sequences, with the ten most expanded clonotypes within a sample referred to 
as major; otherwise they were considered as "singletons". The relative frequency of each 
clonotype/sample was calculated as the number of rearrangements corresponding to the 
clonotype divided by the total number of productive, filtered-in rearrangements for that 
particular sample. For repertoire analysis, clonotypes rather than single rearrangements 
were considered in order to avoid potential biases due to expansion following antigenic 
stimulation, i.e. individual TRBV gene frequencies within a sample were calculated as the 
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number of clonotypes using particular TRBV genes over the total number of clonotypes. 
 
Comparison to healthy controls and public data mining 
We performed clonotype comparison across all 32 CLL patients, as well as against the two 
healthy controls. Clonotypes from replicate samples as well as CD4+ and CD8+ T-cell 
clonotypes belonging to the same patient were concatenated, so that all clonotypes of each 
patient would be included in the comparison. The 10 most expanded clonotypes of each CLL 
sample, referred to as "major clonotypes", were compared to all clonotypes of the healthy 
controls (n=248,593), as well as a panel of 6,318 non-redundant, well-annotated, unique 
clonotypes from various entities, available to our group (n=2,316) or retrieved from the 
IMGT/LIGM-DB sequence database (http://www.imgt.org/IMGTindex/LGM.html) (n=4,002).  
 
HLA typing 
Typing of the HLA-A, -B, -C loci for low resolution and HLA-DRB1 locus for allelic level high-
resolution determination was performed as described previously (19). 
 
Statistical analysis and visualization tools 
Descriptive statistics for discrete parameters included counts and frequency distributions. 
For quantitative variables, statistical measures included means, medians, and min-max 
values. The significance of bivariate/multivariate relationships between variables was 
assessed using the unpaired t-test, and the non-parametric Kruskal Wallis and Mann-
Whitney tests. Cox-regression and hazard ratio tests were applied for assessing the 
predictive value of T-cell clonality regarding time-to-first-treatment (TTFT). TTFT was 
evaluated from the sampling date until the date of initial treatment;  untreated cases were 
censored at the time of last follow-up. For all comparisons a significance level of p=0.05 was 
set. All statistical analyses were performed using the statistical Package GraphPad Prism 
version 5.03 (GraphPad Software, Inc., San Diego, USA).  
 
Data  access 
Raw TR sequence data discussed can be found under accession number SRR3737053 in 
GenBank sequence database (www.ncbi.nlm.nih.gov/genbank/). 
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RESULTS 
 
The T-cell repertoire of CLL is skewed, especially in CD8+ T cells  
Overall, 19,513,078 filtered-in sequences were obtained. Only productive TRBV-TRBD-TRBJ 
rearrangements were evaluated (85.7% of filtered-in sequences, median 324,058/sample). 
For repertoire analysis, clonotypes (i.e. TRB rearrangements with identical TRBV gene usage 
and amino acid CDR3 sequence) were considered. The median number of distinct 
clonotypes/sample was 34,554 (range: 2,193-166,078); the median numbers of expanded 
clonotypes and singletons/sample were 12,507 (range: 812-57,035) and 21,778 (range: 
1,381-122,586), respectively.  
Only 6 genes [TRBV12-3/12-4 (8.4%), TRBV29-1 (6.9%), TRBV27 (6.7%), TRBV19 (6.2%), 
TRBV7-9 (5.4%), and TRBV6-5 (5.1%)] accounted for more than one-third of the repertoire. 
No significant TRBV gene repertoire differences were identified between U-CLL versus M-CLL 
or amongst different stereotyped subsets. Of note, the frequency of individual TRBV genes 
differed significantly when comparing the CLL CD8+ versus CD4+ T-cell repertoire. In 
particular, the TRBV27 and TRBV7-9 genes predominated in CD8+ versus CD4+ T cells (6.4% 
versus 3.9%, p=0.001 and 4.6% versus 2.6%, p=0.001, respectively), whereas the opposite 
held for the TRBV5-1 and TRBV7-2 genes (4.0% versus 6.8%, p=0.001 and 3.1% versus 6.0%, 
p=0.002, respectively) (Supplemental Tables 5-6). 
Asymmetric TRBV gene usage characterized healthy samples as well, although the small 
number of samples analyzed precludes comprehensive healthy TRBV gene repertoire 
analysis (Supplemental Table 7). However, the CLL TRB repertoire was significantly more 
oligoclonal compared to healthy controls as reflected in a median cumulative frequency of 
the 10 most expanded clonotypes/sample of 23.6% in CLL versus 5.1% in healthy controls 
(p<0.05) (Figure 1A; Supplemental Table 8).  
To investigate whether T-cell clonality is associated to disease course, we evaluated TTFT in 
22/24 CLL patients for whom PBMC samples were tested (measured from the date of 
sampling, when T-cell clonality was assessed, until the date of treatment or last follow-up 
date for untreated patients). The cumulative frequency of the 10 most expanded 
clonotypes/patient did not reach statistical significance as an independent predictor for TTFT 
when treated as a quantitative variable (p=0.54). When we divided our patients into 2 
clonality categories, above (n=11) or below (n=11) the median cumulative frequency of the 
10 most expanded clonotypes (22.3%), we found that the former category was associated 
©    2016 Macmillan Publishers Limited. All rights reserved.
Vardi et al, High-throughput immunoprofiling of the T-cell repertoire in CLL 
10 
 
with higher probability for treatment need, albeit without reaching statistical significance 
(Hazard ratio 1.7, p=0.34).  
The distinct CLL immunogenetic subgroups analyzed did not exhibit major differences 
regarding oligoclonality. Clonality stemmed mainly from the CD8+ T-cell compartment, 
where the median cumulative frequency of the 10 most expanded clonotypes/sample was 
43.6% versus only 5.3% for the CD4+ T-cell samples, respectively (p<0.001) (Figure 1B, 
Supplemental Table 8).  
 
Longitudinal analysis reveals clonal persistence 
To assess clonal dynamics over time, one subset #2 and two subset #4 CLL patients were 
studied longitudinally, in two successive time points (median sampling interval 23 months). 
For the patient assigned to subset #2, PBMCs were analyzed in both time points. The TRBV 
gene repertoire remained remarkably stable overtime (Figure 2A). For the two subset #4 
patients, the first time point involved PBMC analysis, whereas the second time point 
involved analysis of isolated CD4+ and CD8+ T-cell subpopulations, therefore TRBV gene 
repertoire comparison was not performed.  
Major clonotypes (i.e. the 10 most expanded clonotypes/sample) were found to persist in all 
three studied cases. In the subset #2 case, 10.4% (3970/38054) of all clonotypes and 17.4% 
(2286/13134) of all expanded clonotypes from the first time point persisted over time. 
Interestingly, in the second time point the persisting clonotypes constituted a larger fraction 
of the total repertoire (31.9% of all clonotypes and 40.9% of all expanded clonotypes, 
respectively). In the two subset #4 patients, 14.9% (2576/17250) and 27.6% (9918/35962) of 
all clonotypes identified in the PBMC samples were found in subsequent time points (11.8% 
and 21.0% retained in the CD4+ T-cell compartment, and 3.1% and 6.6% retained in the CD8+ 
T-cell compartment, respectively). Similarly, 16.7% (1247/7455) and 35.3% (4984/14125) of 
all expanded clonotypes identified in the PBMC samples persisted in the following time 
points (13.1% and 26.8% retained in the CD4+ T-cell compartment, and 3.6% and 8.5% 
retained in the CD8+ T-cell compartment, respectively). Most major persisting clonotypes 
were contained within the CD8+ T-cell subpopulation (Figure 2B). 
 
Shared T-cell receptor clonotypes in CLL: mostly disease-specific  
Comparisons across CLL patients and against the two healthy controls revealed that 
162,179/2,464,321 (6.6%) CLL clonotypes were shared by two or more patients, 96.8% of 
which were not found in either healthy control. Most (79.2%) public CLL clonotypes 
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concerned pairs of patients, and few were found in 3 (13.3%) or ≥4 (7.5%) CLL patients. No 
pattern of similar disease characteristics was discerned among patients sharing clonotypes. 
Highly similar results were obtained when performing the same analysis excluding singletons 
(data not shown). 
In most cases, public CLL clonotypes were low-frequent. Hence, we performed the same 
analyses considering only the major clonotypes of each CLL sample and found: (i) two major 
clonotypes shared among 2 pairs of subset #4 patients, (ii) one major clonotype shared 
among a pair of subset #1 patients (iii) one major clonotype shared among a subset #1 and a 
subset #2 patient, and, (iv) two major clonotypes shared among CLL patients belonging to 
different immunogenetic subgroups (i.e. subset and non-subset cases); one of these was 
identified in healthy controls, albeit at very low frequencies (0.04% and 0.0005%, 
respectively). In all subset cases sharing major clonotypes, HLA typing revealed relevant HLA 
restrictions (Table 1, Supplemental Table 9).  
We next performed cross-entity comparisons among the identified CLL major clonotypes 
and a panel of 6,318 non-redundant, unique clonotypes from various entities  deposited in 
the IMGT/LIGM-DB sequence database or available to our group. As shown in Table 1, only a 
single public major CLL clonotype matched with a public database entry, corresponding to a 
T-large granular lymphocytic leukemia (LGL) patient. This clonotype was not subset-specific, 
but rather shared between a subset #4 patient and a M-CLL patient not assigned to any 
stereotyped subset. Among the patient-specific (‘private’) CLL major clonotypes, we found 
matches with: (i) two EBV-specific clonotypes, (ii) a T-cell clonotype identified in a T-LGL 
patient, and, (iii) a T-cell clonotype from an individual with CLL-like monoclonal B-cell 
lymphocytosis (MBL), a condition considered as premalignant to CLL. Additionally, we found 
a match between a CD4+ T-cell clonotype belonging to a subset #1 patient (P17) with a T-cell 
clonotype from another subset #1 CLL patient previously analyzed by our group through 
classic subcloning and Sanger sequencing (Table 2): this pair of subset #1 patients shared the 
HLA-DRB*13:03 allele. Hence, overall, public clonotypes shared between different CLL cases 
were mostly disease-specific, i.e. not found amongst other entities. 
 
Clonotype sharing in different tissue microenvironments 
For one subset #1 patient, synchronous peripheral blood and lymph node samples were 
tested. The TRBV gene repertoire was almost identical in both samples (Figure 3A). The 
extent of clonality was also similar. In particular, the median cumulative frequency of the 10 
most expanded clonotypes/sample was 8.8% in PBMCs versus 7.3% in the lymph node and 
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the percentage of expanded clonotypes over the total repertoire of each sample was 37.2% 
(15072/40503) versus 38.1% (15639/41010), respectively. Overall, 18.7% (7576/40503) 
clonotypes and 24.5% (3696/15072) expanded clonotypes identified in the PBMC sample 
were also identified in the lymph node sample, including two of the major clonotypes that 
were common for both tissue samples (Figure 3B).   
 
Replicates 
First, we examined "sample replicates" i.e. used aliquots of peripheral blood containing 
varying numbers of T cells (1 quadruplicate and 2 duplicates). Overall, despite limited 
fluctuation of the TRBV gene repertoire, the dominant T-cell clonotypes showed remarkable 
consistency for the tested T-cell range (0.5-18 x 106 cells), proving that sample quantity 
ensured adequate repertoire profiling depth (Supplemental Figures 1,2).  
We then examined "PCR replicates", i.e. starting from the same RNA sample (1 
quadruplicate and 2 duplicates), containing varying RNA quantity. Again, limited fluctuations 
of the TRBV gene repertoire were noted in few instances, however the dominant T-cell 
clonotypes were practically identical, ensuring that both cDNA and NGS library preparation 
protocols are robust, at least for the RNA range tested (1.0-5.8 μg) (Supplemental Figures 
3,4). 
Finally, we examined "sequencing replicates", i.e. starting from the same PCR product but 
sequenced in separate MiSeq runs, and actually different MiSeq machines (5 duplicates). 
Both the TRBV gene repertoire and the dominant clonotypes were remarkably consistent, 
proving that the sequencing procedure is indeed reproducible (Supplemental Figures 5,6). 
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DISCUSSION 
 
NGS immunoprofiling holds the potential to reveal the architecture of complex repertoires, 
however still presents limitations and pitfalls. For the present analysis of the TRB repertoire 
in CLL, we followed a systematic and stringent approach including multiple controls, and 
focused on CLL cases assigned to the most populated and best-characterized CLL 
stereotyped subsets representing distinct entities with opposite clinical course and outcome 
(2). We also included CLL patients carrying non-subset BcR IG rearrangements investigating 
whether certain T-cell immunogenetic features may be ubiquitous in CLL, regardless of the 
particular IG receptor that is expressed. 
Our findings provide solid evidence for T-cell oligoclonality in all CLL patients analyzed, 
stemming mainly from the CD8+ T-cells. A similar extent of TR oligoclonality was noted 
between patients with distinct BcR IG, thus sharply contrasting the polyclonal profile of age-
matched healthy controls, suggestive of antigenic selection. That said, the TRBV gene 
frequency distribution did not differ significantly between CLL patients and healthy controls, 
prompting speculations that it might reflect either differential primer amplification efficacies 
or naturally occurring preferential TRBV gene rearrangements (21, 22). Nevertheless, the 
statistically significant differences observed between CD4+ versus CD8+ TRBV gene repertoire 
favor the latter scenario. 
A major finding of the present study concerned clonal persistence over time in CLL patients 
belonging to different immunogenetic subgroups of the disease (i.e. subsets #2 and #4). 
Importantly, the persisting clonotypes, found within both the CD4+ and CD8+ T-cell 
compartments, constituted a larger fraction of the total repertoire in subsequent time 
points in all tested cases. Most major persisting clonotypes corresponded to CD8+ T-cells, 
however this might be attributed to the greater extent of clonality in the CD8+ T-cell 
repertoire. On these grounds, it is reasonable to argue that the selecting antigens are also 
persistent, driving the respective T-cell clones to further expansion. Despite the small 
number of samples analyzed, clonal persistence was evident in two distinct immunogenetic 
subgroups of the disease with sharp clinicobiological differences (i.e. subsets #2 and #4), 
thereby alluding to a generic CLL characteristic. It would be interesting to test this 
hypothesis in more CLL samples, including cases that are not assigned to any stereotyped 
subset. That said, ongoing interactions with the selecting antigen(s) emerge as a recurring 
theme in CLL pathobiology, being evident in both the clonotypic IGs (most notably in subset 
#4) (23-26) and the TRs of the reactive T cells. 
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As expected for individuals who are not HLA-matched, most of the identified clonotypes 
were patient-specific (“private”) and only few were "public", i.e. shared by ≥2 patients. 
Moreover, most "public" clonotypes were represented at low frequencies, therefore had 
dubious biological significance. However, and perhaps of most biological relevance, we also 
identified major clonotypes shared between different patients. These public major 
clonotypes tended to cluster among pairs of patients assigned to the same stereotyped 
subset, where the CLL cells are most likely selected by shared antigenic elements (27, 28). 
Interestingly, they were not identified in the examined healthy controls, despite both 
expressing HLA-A*24, i.e. fulfilling the identified HLA restriction for at least one major 
clonotype shared among two subset #1 patients. Overall, the aforementioned findings allude 
to selection of the T-cell repertoire by restricted antigenic epitopes in a subset-specific 
context. Thus, they raise the possibility that the implicated antigens might be those selecting 
the CLL progenitors or even the malignant cells themselves. Alternatively, they could 
correspond to CLL subset-specific IG structures acting as idiotypic neoantigens (29).  Recent 
work combining crystallographic and functional studies provided exciting novel results 
regarding the epitopes involved in homotypic CLL BcR interactions. Such epitopes appear to 
indeed be subset-specific, thus elucidating the structural basis of autonomous activation of 
CLL B-cells and reconciling the existence of a shared pathogenetic mechanism with the 
distinct clinicobiological profiles of CLL subsets (30). In light of these findings, these subset-
specific epitopes could be tested as to whether they might be recognized/bound by cognate 
T cells. If successful, such endeavors will assist in clarifying the nature of antigenic elements 
that are responsible for T-cell repertoire skewing in CLL. 
In conclusion, massive parallel sequencing documents the pronounced skewing of the TR 
repertoire in CLL, supporting selection by restricted antigenic elements. These elements 
appear to persist over time, driving the respective T-cell clones to further expansion. 
Expanded clonotypes are shared among patients, most especially among those assigned to 
the same stereotyped subset. Whether they recognize the same antigens interacting with 
the malignant clone or tumor-associated epitopes, possibly contained within the idiotypic 
IG, remains to be elucidated and may be of particular benefit in light of the clinical testing of 
immune checkpoint inhibitors, designed to boost endogenous T-cell anti-tumor responses 
(18, 31-32).   
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FIGURE LEGENDS  
 
Figure 1. CLL T-cell repertoire is oligoclonal, with clonality stemming mainly from CD8+ T 
cells. A. T-cell clonality analysis for each immunogenetic CLL subgroup (subset #1, subset #2, 
subset #4 and cases with heterogeneous BcR IG rearrangements) versus healthy individuals. 
Each lane corresponds to a single PBMC sample (replicate PBMC samples have been 
excluded). B. T-cell clonality analysis in CD8+ versus CD4+ T-cells. Here, each lane corresponds 
to a CD4+ or CD8+ T-cell sample from CLL patients.  
The colored tiles of each lane depict the relative size of the 10 most expanded clonotypes 
within the respective sample. The outer tile (shown in white in all instances) depicts the 
polyclonal background, i.e. the cumulative frequency of all other clonotypes within the 
sample.  
 
Figure 2. Over time analysis of the TRBV repertoire and clonal drift. A. The TRBV gene 
repertoire in a subset #2 CLL patient remains stable over time. The 10 most frequent TRBV 
genes are depicted. B. Each column represents the 10 most expanded clonotypes within the 
tested sample. The persisting clonotypes for each patient are depicted with the same color. 
The lower tile (shown in white in all instances) contains major clonotypes that were not 
identified within the 10 most expanded clonotypes of the respective longitudinal sample. 
Major clonotypes persist in all 3 CLL cases tested.  
 
Figure 3. Repertoire comparisons in synchronous PBMC and lymph node samples. A. The 
TRBV gene repertoire is almost identical in the two tissues. The 10 most frequent TRBV 
genes are depicted. B. Two major clonotypes are common among the two tissue samples 
(shown in color). The lower tile (shown in white) contains the remaining 8 major clonotypes 
of each sample. 
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Patient 
ID 
Immunogenetic 
subgroup 
Sample 
type 
TRBV 
GENE 
CDR3 AMINO ACID 
SEQUENCE 
matches with  
public database 
clonotypes or 
healthy controls 
HLA 
restriction 
P8 subset #4 PBMCs 
TRBV7-2 ASSLSGRGPLGSNQPQH 
no hit with 
PDB/healthy 
HLA-A*02 
P9 subset #4 CD8+ 
P8 subset #4 PBMCs 
TRBV19 ASTRQGTGELF 
no match with 
PDB/healthy 
HLA-A*02 
or HLA-B*51 P3 subset #4 PBMCs 
P15 subset #1 BM 
TRBV12-3 ASSSTGGTGELF 
no match with 
PDB/healthy 
HLA-A*24 
P13 subset #1 LN 
P16 subset #1 PBMCs 
TRBV19 ASSQGAGNTIY 
no match with 
PDB/healthy 
HLA-A*02 
P32 subset #2 PBMCs 
P18 M-CLL, IGHV4-34 CD8+ 
TRBV29-1 SVGTGGTNEKLF 
Large granular 
lymphocytic 
leukemia 
ND 
P3 subset #4 PBMCs 
P16 subset #1 PBMCs 
TRBV5-1 ASRGGEKLF 
Match with healthy 
 
ND 
P22 subset #2 BM 
P25 UM-CLL, IGHV4-34 PBMCs 
P30 UM-CLL, IGHV3-21 PBMCs 
 
Table 1. Shared major clonotypes amongst CLL patients. 
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Patient 
ID 
Immunogenetic 
subgroup 
TRBV gene 
CDR3 AMINO ACID 
SEQUENCE 
Entity 
description 
PDB Accession No 
P23 M-CLL, IGHV4-34  TRBV10-3 AIGTGDSNQPQH EBV 
AM041168, 
AM041175 
P31 M-CLL, IGHV3-21 TRBV10-3  ASGTGDSNQPQH EBV AM041172 
P11 subset #4 TRBV19 ASSIGTGELF LGL   
P32 subset #2 TRBV12-3  ASSPNYSNQPQH MBL   
P17 subset #1 TRBV6-5 ASSRAGQPQH CLL, subset #1 
  
Table 2. CLL major clonotype matches with public database sequences. 
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